Increased competition on influenza vaccine

The British GSK returns in 2022 on the French market, occupied by Sanofi and Mylan.

This year again, the shadow of the Covid should hang over the flu vaccination campaign. It is still too early to assess the appetite of the French. After two doses of Covid vaccines and soon a third for the most vulnerable, weariness could be the order of the day. However, in a context of circulation of influenza and SARS-Cov-2, doctors warn about “the risks of superinfection»And the difficulties in diagnosing the two diseases with fairly similar symptoms. If the flu did not circulate last year, ousted by the Covid, sporadic cases have appeared since the start of the school year. The reduction of barrier gestures could promote its circulation.

Last year, when Covid vaccines were not yet available, the French – and especially the most fragile (over 65, chronically ill …) – rushed into pharmacies. If the objective of 75% vaccination coverage of target populations had not been reached, we had come close to it.

This article is for subscribers only. You have 75% left to discover.

To cultivate one’s freedom is to cultivate one’s curiosity.

Continue reading your article for € 1 the first month

Already subscribed? Log in


Leave a Comment

This site uses Akismet to reduce spam. Learn how your comment data is processed.